Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
A phase 2 trial of Adagrasib in metastatic cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.
Overview
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) is a phase 2 interventional study registered as NCT05853575 by Mirati Therapeutics Inc., with 200 participants planned, started 2024-02-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: Adagrasib. Conditions listed: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
- TrialPhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G
Shares Adagrasib, Bristol Myers Squibb.
- TrialA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
- TrialA Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
- TrialA Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
- TrialA Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Shares Adagrasib, Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
- TrialA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
- TrialCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Shares Adagrasib, Bristol Myers Squibb.